Incannex Healthcare added to S&P/ASX 300 Index
The addition was made following S&P Dow Jones Indices’ September quarterly review and will take effect prior to the market opening on September 19, 2022.
Company
Incannex Healthcare Inc
NASDAQ:IXHL
Incannex Healthcare Inc is a clinical-stage biopharmaceutical company leading the way in developing combination therapeutics that target underlying biological pathways associated with chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. The company's strategy is to advance novel therapies by leveraging evidence-based innovation with the potential to transform the lives of people suffering from these conditions.
55 stories · page 3 of 3
Incannex Healthcare’s new board member brings invaluable global regulatory experience
Clark will be able to assist IHL with acquisitions, compliance and due diligence having managed regulatory aspects of large-scale pharmaceutical acquisitions at senior levels.
Incannex Healthcare acquires APIRx; unlocks 'world’s largest' portfolio of medicinal cannabis patents
“After extensive due diligence and corporate strategy assessments of the APIRx assets, we are excited and readied to commence development activities over our newly acquired portfolio of drug candidates," MD and CEO Joel Latham said.
Incannex Healthcare partners with R&D organisation Curia to scale-up manufacture of drug targeting traumatic brain injury
"Its manufacture will facilitate investigation of the product in the well-controlled clinical trials we are designing, with feedback from FDA, to assess the safety and therapeutic benefit in patients with traumatic brain injuries," chief sc
Incannex Healthcare receives ethics approval to start phase 1 clinical trial for CBD anti-inflammatory drug
Ethics approval gives IHL the green light to test its proprietary multi-use, anti-inflammatory drug IHL-675A which comprises a combination of cannabidiol and hydroxychloroquine.
Incannex Healthcare fields positive results from Phase 2 clinical trial investigating IHL-42X for treatment of obstructive sleep apnoea
Incannex's IHL-42X sleep aponea treatment demonstrated higher levels of efficacy than other unregistered monotherapies while maintaining a lower adverse event incidence than placebo at the lowest administered dose.
Incannex Healthcare has positive FDA pre-IND meeting on IHL-42X for obstructive sleep apnoea
"The agency’s responses to the specific questions we posed allow us to revise our clinical trial protocols, to ensure that we are running highly efficient studies that generate the type and amount of data the FDA will require in a future ma
Incannex Healthcare enters share sale and purchase agreement for APIRx Pharmaceuticals USA, shares up
“The acquisition of APIRx presents us with clear long and short-term opportunities for significant value growth”, says MD Joel Latham.
Incannex Healthcare's IHL-216A treatment observed to have neuroprotective effect in rodent model of sports concussion
“The data also gives us the confidence to proceed to clinical development, the first step of which is preparing for a pre-IND meeting with the FDA to get confirmation that our proposed clinical development strategy is acceptable,” said chie
Incannex Healthcare raises A$23.6 million to help ramp up R&D
The clinical-stage pharmaceutical company will use the money raised to ramp up research and development activities in 2022 and 2023.
Incannex Healthcare moves to acquire biotech company APIRx Pharmaceuticals USA
“We believe that bringing together Incannex and APIRx will bolster our position as a leader in the medicinal cannabinoid sector and will further set IHL apart from other players in the industry," says IHL's CEO and MD.
Incannex Healthcare to offer loyalty options to reward shareholders and fund next phase of development
“Our research is highly focused on completing the clinical trials necessary to commercialise our sophisticated cannabinoid and psychedelic medicines developed for prescription, or administration, by health professionals,” says CEO Joel Lath
Incannex observes progress for obstructive sleep apnoea patients in preliminary results of proof-of-concept trial
“IHL-42X has the potential to reduce disease severity, resulting in improved sleep quality, multiple major health benefits and increased quality of life,” said chief scientific officer Mark Bleackley.
Incannex Healthcare and Monash University execute licence deal to develop combination VR and psychedelic treatment
“The combination of psychedelic compounds with an evidence-based VR therapy is leading-edge in the field of mental health treatments. We look forward to providing more detail about the project in due course when clinical trial planning has
Incannex Healthcare now listed on the Nasdaq
“The ringing of the closing bell to commemorate the listing of our ADSs was a milestone for Incannex, as we advance our pipeline of novel synthetic cannabinoid and psychedelic agents through the clinic,” stated MD & CEO.